Do analysts rate CDIO or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CDIO or QNTM?

In the previous week, Quantum Biopharma had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Cardio Diagnostics. Quantum Biopharma's average media sentiment score of 0.91 beat Cardio Diagnostics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALVR or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ALVR or CDIO?

In the previous week, AlloVir and AlloVir both had 1 articles in the media. AlloVir's average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AlloVir 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DARE or CDIO?

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 627.27%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to DARE or CDIO?

In the previous week, Dare Bioscience had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Cardio Diagnostics. Dare Bioscience's average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CDIO or LPCN?

Lipocine has a consensus target price of $15.00, indicating a potential upside of 590.61%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Does the media prefer CDIO or LPCN?

In the previous week, Lipocine had 3 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for Lipocine and 1 mentions for Cardio Diagnostics. Lipocine's average media sentiment score of 0.75 beat Cardio Diagnostics' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer JSPR or CDIO?

Jasper Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 1,726.48%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to JSPR or CDIO?

In the previous week, Jasper Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Cardio Diagnostics. Jasper Therapeutics' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardio Diagnostics (CDIO) Competitors

$1.70 +0.04 (+2.41%)

As of 09:58 AM Eastern

Compare

CDIO vs. QNTM, ALVR, DARE, LPCN, and JSPR

Should you buy Cardio Diagnostics stock or one of its competitors? MarketBeat compares Cardio Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardio Diagnostics include Quantum Biopharma (QNTM), AlloVir (ALVR), Dare Bioscience (DARE), Lipocine (LPCN), and Jasper Therapeutics (JSPR).

How does Cardio Diagnostics compare to Quantum Biopharma?

Cardio Diagnostics (NASDAQ:CDIO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

In the previous week, Quantum Biopharma had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Cardio Diagnostics. Quantum Biopharma's average media sentiment score of 0.91 beat Cardio Diagnostics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cardio Diagnostics has higher revenue and earnings than Quantum Biopharma. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$16.57K	303.77	-$6.50M	-$3.38	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Quantum Biopharma has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Cardio Diagnostics' return on equity of -78.82% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Quantum Biopharma	N/A	-941.54%	-224.41%

Cardio Diagnostics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Summary

Cardio Diagnostics beats Quantum Biopharma on 8 of the 12 factors compared between the two stocks.

How does Cardio Diagnostics compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

AlloVir has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. AlloVir's return on equity of -71.03% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

In the previous week, AlloVir and AlloVir both had 1 articles in the media. AlloVir's average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AlloVir	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardio Diagnostics has higher revenue and earnings than AlloVir. Cardio Diagnostics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Cardio Diagnostics	$16.57K	303.77	-$6.50M	-$3.38	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

AlloVir beats Cardio Diagnostics on 6 of the 11 factors compared between the two stocks.

How does Cardio Diagnostics compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Dare Bioscience has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market.

In the previous week, Dare Bioscience had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Cardio Diagnostics. Dare Bioscience's average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Dare Bioscience's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Cardio Diagnostics has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	20.13	-$13.40M	-$0.95	N/A
Cardio Diagnostics	$16.57K	303.77	-$6.50M	-$3.38	N/A

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 627.27%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Dare Bioscience beats Cardio Diagnostics on 9 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Lipocine?

Cardio Diagnostics (NASDAQ:CDIO) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Cardio Diagnostics has higher earnings, but lower revenue than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$16.57K	303.77	-$6.50M	-$3.38	N/A
Lipocine	$1.57M	11.41	-$9.63M	-$1.79	N/A

In the previous week, Lipocine had 3 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for Lipocine and 1 mentions for Cardio Diagnostics. Lipocine's average media sentiment score of 0.75 beat Cardio Diagnostics' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lipocine has a consensus target price of $15.00, indicating a potential upside of 590.61%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by insiders. Comparatively, 4.7% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lipocine has a net margin of -755.39% compared to Cardio Diagnostics' net margin of -36,950.00%. Lipocine's return on equity of -64.75% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Lipocine	-755.39%	-64.75%	-57.62%

Cardio Diagnostics has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Summary

Lipocine beats Cardio Diagnostics on 11 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Cardio Diagnostics. Jasper Therapeutics' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jasper Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 1,726.48%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jasper Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Cardio Diagnostics' return on equity of -78.82% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Cardio Diagnostics has higher revenue and earnings than Jasper Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Cardio Diagnostics	$16.57K	303.77	-$6.50M	-$3.38	N/A

Jasper Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

Summary

Jasper Therapeutics beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.00M	$3.67B	$6.97B	$12.95B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	-0.50	8.43	270.87	25.95
Price / Sales	303.77	1,289.64	666.62	110.60
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	0.45	18.28	13.29	6.22
Net Income	-$6.50M	-$13.22M	$3.45B	$342.81M
7 Day Performance	8.97%	5.77%	4.21%	3.97%
1 Month Performance	-10.99%	-3.77%	-1.96%	-1.33%
1 Year Performance	-56.07%	58.26%	76.81%	21.98%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	0.6381 of 5 stars	$1.70 +2.4%	N/A	-57.9%	$5.00M	$16.57K	N/A	1	Positive News Upcoming Earnings
QNTM Quantum Biopharma	0.7465 of 5 stars	$2.84 -5.5%	N/A	-87.6%	$18.14M	N/A	N/A	N/A
ALVR AlloVir	N/A	$3.58 -4.0%	N/A	+64.3%	$18.05M	N/A	N/A	110	High Trading Volume
DARE Dare Bioscience	2.2055 of 5 stars	$1.20 +0.8%	$10.00 +736.8%	-41.2%	$18.02M	$1.03M	N/A	30	News Coverage Upcoming Earnings Gap Down
LPCN Lipocine	3.247 of 5 stars	$2.12 -1.2%	$15.00 +609.2%	-29.5%	$17.68M	$2.00M	N/A	10	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. QNTM, ALVR, DARE, LPCN, and JSPR

How does Cardio Diagnostics compare to Quantum Biopharma?

Summary

How does Cardio Diagnostics compare to AlloVir?

Summary

How does Cardio Diagnostics compare to Dare Bioscience?

Summary

How does Cardio Diagnostics compare to Lipocine?

Summary

How does Cardio Diagnostics compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. QNTM, ALVR, DARE, LPCN, and JSPR

How does Cardio Diagnostics compare to Quantum Biopharma?

Does the media prefer CDIO or QNTM?

Do analysts rate CDIO or QNTM?

Do insiders and institutionals have more ownership in CDIO or QNTM?

Which has preferable valuation & earnings, CDIO or QNTM?

Is CDIO or QNTM more profitable?

Which has more risk and volatility, CDIO or QNTM?

Summary

How does Cardio Diagnostics compare to AlloVir?

Which has more volatility and risk, ALVR or CDIO?

Is ALVR or CDIO more profitable?

Does the media refer more to ALVR or CDIO?

Which has better earnings and valuation, ALVR or CDIO?

Do analysts prefer ALVR or CDIO?

Do institutionals and insiders have more ownership in ALVR or CDIO?

Summary

How does Cardio Diagnostics compare to Dare Bioscience?

Which has more volatility & risk, DARE or CDIO?

Does the media refer more to DARE or CDIO?

Is DARE or CDIO more profitable?

Which has stronger valuation & earnings, DARE or CDIO?

Do analysts prefer DARE or CDIO?

Do insiders & institutionals have more ownership in DARE or CDIO?

Summary

How does Cardio Diagnostics compare to Lipocine?

Which has preferable valuation and earnings, CDIO or LPCN?

Does the media prefer CDIO or LPCN?

Do analysts recommend CDIO or LPCN?

Do insiders and institutionals believe in CDIO or LPCN?

Is CDIO or LPCN more profitable?

Which has more risk & volatility, CDIO or LPCN?

Summary

How does Cardio Diagnostics compare to Jasper Therapeutics?

Do institutionals and insiders believe in JSPR or CDIO?

Does the media refer more to JSPR or CDIO?

Do analysts prefer JSPR or CDIO?

Is JSPR or CDIO more profitable?

Which has higher earnings and valuation, JSPR or CDIO?

Which has more volatility and risk, JSPR or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools